Rituximab,Temelimab
GeNeuro,Biogen,Roche
['imab ', 'geneuro']
geneuro s protect-ms phase 2 trial data, presented at the ectrims 2022 congress in amsterdam, confirms synergistic neuroprotective potential of temelimab in ms 
Breaking news from Business Wire